Publications

Detailed Information

The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients

Cited 27 time in Web of Science Cited 31 time in Scopus
Authors

Lim, Jeong-Hoon; Kwon, Soie; Jeon, Yena; Kim, Young Hoon; Kwon, Hyunwook; Kim, Yon Su; Lee, Hajeong; Kim, Yong-Lim; Kim, Chan-Duck; Park, Sun-Hee; Lee, Jong Soo; Yoo, Kyung Don; Son, Hyung Eun; Jeong, Jong Cheol; Lee, Jeonghwan; Lee, Jung Pyo; Cho, Jang-Hee

Issue Date
2022-09
Publisher
Lippincott Williams & Wilkins Ltd.
Citation
Transplantation, Vol.106 No.9, pp.E404-E412
Abstract
Background. The efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have not been investigated in kidney transplant recipients (KTRs) with diabetes. We evaluated the impact of SGLT2i in a multicenter cohort of diabetic KTRs. Methods. A total of 2083 KTRs with diabetes were enrolled from 6 transplant centers in Korea. Among them, 226 (10.8%) patients were prescribed SGLT2i for >90 d. The primary outcome was a composite outcome of all-cause mortality, death-censored graft failure (DCGF), and serum creatinine doubling. An acute dip in estimated glomerular filtration rate (eGFR) over 10% was surveyed after SGLT2i use. Results. During the mean follow-up of 62.9 +/- 42.2 mo, the SGLT2i group had a lower risk of primary composite outcome than the control group in the multivariate and propensity score-matched models (adjusted hazard ratio, 0.43; 95% confidence interval, 0.24-0.78; P = 0.006 and adjusted hazard ratio, 0.45; 95% confidence interval, 0.24-0.85; P = 0.013, respectively). Multivariate analyses consistently showed a decreased risk of DCGF and serum creatinine doubling in the SGLT2i group. The overall eGFR remained stable without the initial dip after SGLT2i use. A minority (15.6%) of the SGLT2i users showed acute eGFR dip during the first month, but the eGFR recovered thereafter. The risk factors for the eGFR dip were time from transplantation to SGLT2i usage and mean tacrolimus trough level. Conclusions. SGLT2i improved a composite of all-cause mortality, DCGF, or serum creatinine doubling in KTRs. SGLT2i can be used safely and have beneficial effects on preserving graft function in diabetic KTRs.
ISSN
0041-1337
URI
https://hdl.handle.net/10371/185553
DOI
https://doi.org/10.1097/TP.0000000000004228
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share